Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
3-Aminoxypropionate-based linker system for cyclization activation in prodrug designYiyu Ge, Xinghua Wu, Dazhi Zhang, et al.
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents|September 6, 2022
Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutationsJun Wang, Daniel Lam, Jeffrey Yang, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2012
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activationYanhui Yang, Andrew Voak, Shane R Wilkinson, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2009
Exploiting the drug-activating properties of a novel trypanosomal nitroreductaseBelinda S Hall, Xinghua Wu, Longqin Hu, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|November 25, 2017
Enantiomeric characterization and structure elucidation of LH601A using vibrational circular dichroism spectroscopyJian Shen, Sadagopan Magesh, Lin Chen, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 23, 2020
Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein InteractionSumi Lee, Dhulfiqar Ali Abed, Lesa J Beamer, et al.
Acta Pharmaceutica Sinica. B|November 19, 2015
Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agentsDhulfiqar Ali Abed, Melanie Goldstein, Haifa Albanyan, et al.
Accounts of Chemical Research|January 28, 2022
Disrupting Crystal Growth through Molecular Recognition: Designer Therapies for Kidney Stone PreventionAlexander G Shtukenberg, Longqin Hu, Amrik Sahota, et al.
Pageof 7